Amgen sets $ 21,900 annual price for new Evenity bone drug

(Reuters) – Alternative Inc. on Monday set the U.S. a $ 1,825 a month, or $ 21,900 for a full 12-month course of injections.

PHOTO FILE: In the South San Francisco, California in this October 21, 2013 photo file. REUTERS / Robert Galbraith / Files

The U.S. Food and Drug Administration last week approved bone fracture

Back to sales

Analysts, on average, Evening revenue project to $ 274 million and year by 2024, according to IBES data from Refinitiv.

Prolia is not a build bone from Evenity does. It is designed to block and protein that activates bone-destroying cells called osteoclasts.

. T

“We are priced in this phone,” Murdo Gordon, executive president of global commercial operations at Amgen, told Reuters in a phone interview.

Since rival bone-building drugs Tymlos, has been sold by Radius Health. T

Tymlos and Forteo are the parathyroid hormone drugs.

Ity It is administered by physicians every month for a year

“This is because the disease is caused by the disease,” said Mr Gordon. “There have been very limited options for women who have had a fracture.”

Reporting By Deena Beasley; Editing by Bill Berkrot

Our Standards:The Thomson Reuters Trust Principles.


Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.